20
Oct

While its merger with AbbVie is looking dead, Shire is likely in line for a $1.6 billion breakup fee, cash that could fund a major M&A push. And with renowned dealmakers in its executive ranks, Shire may not be lonely for long.

…read more

Source: Left at the altar by AbbVie, Shire has cash, options and an M&A pedigree

    

0 No comments